Transcode Therapeutics, Inc. (RNAZ) shareholders
Close on Nov 17, 2026Market cap $1.43MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Defj, LLC Joint filing with CK Life Sciences Int'l., (Holdings) Inc. (83.90%) | 14,134,481 | 83.90% | 13D (active) amendment | Aug 3, 2026 |
| Thomas A. Fitzgerald | 422,036 | 5.50% | 13D (active) | Jun 21, 2024 |
| Unleash Immuno Oncolytics, Inc. | 300,000 | 9.94% | 13G (passive) | Jul 23, 2026 |
| Elena Rosa Braci | 186,236 | 6.17% | 13G (passive) | Jul 23, 2026 |
| Daniel Eduardo Katzman | 155,611 | 5.16% | 13G (passive) | Jul 23, 2026 |
| SC-Sigma Global Partners, LP Joint filing with YA II PN, Ltd. (9.90%), YA Global Investments II (U.S.), LP (9.90%) and 5 more | 101,772 | 9.90% | 13G (passive) | Apr 15, 2026 |
| CK Life Sciences Int'l., (Holdings) Inc. Joint filing with Defj, LLC (9.10%) | 83,285 | 9.10% | 13D (active) amendment | Oct 27, 2025 |
| Hal Mintz Joint filing with Sabby Management, LLC (9.90%), Sabby Volatility Warrant Master Fund Ltd (9.90%) | 69,555 | 9.90% | 13G (passive) | Dec 31, 2024 |
| Thomas Joseph Tracy | 35,000 | 5.00% | 13D (active) | Mar 7, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RNAZ | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Yorkville Advisors Global, LP | 19,639 | 0.12% | $121.96K | New | 0.14% |
| Vanguard Capital Management LLC | 6,545 | 0.04% | $40.64K | – | 0.00% |
| Vanguard Fiduciary Trust Co | 2,982 | 0.02% | $18.52K | – | 0.00% |
| UBS Group AG | 2,888 | 0.02% | $17.93K | −5,407 | 0.00% |
| FMR LLC | 706 | 0.00% | $4.38K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 677 | 0.00% | $4.20K | +449 | 0.00% |
| Wells Fargo & Company/Mn | 55 | 0.00% | $342 | – | 0.00% |
| SBI Securities Co., Ltd. | 12 | 0.00% | $75 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 8 | 0M | 0.2% | 2 / 1 | 1 / 2 | 0M | 0M |
| Q1 2026 | 8 | 0M | 0.2% | 4 / 2 | 1 / 2 | 0M | 0M |
| Q4 2025 | 6 | 0M | 0.0% | 1 / 1 | 0 / 3 | 0M | 0M |
| Q3 2025 | 8 | 0M | 0.1% | 3 / 0 | 2 / 4 | 0M | 0M |
| Q2 2025 | 9 | 0M | 0.2% | 1 / 4 | 4 / 11 | 0M | 0M |
| Q1 2025 | 19 | 0M | 0.5% | 14 / 3 | 0 / 0 | 0M | 0M |
| Q4 2024 | 5 | 0M | 0.0% | 5 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
5 funds held RNAZ in Q2 2026, 40% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of RNAZ | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 8,492 | 0.05% | $43.65K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 6,545 | 0.04% | $40.64K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 1,180 | 0.01% | $6.07K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 510 | 0.00% | $2.62K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -199 | -0.00% | -$1.24K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Thomas A. Fitzgerald | Chief Financial Officer, Director | 56,318 | 0.33% | Sep 11, 2026 |
| John A. Tattory | Interim CFO | – | – | Sep 21, 2026 |
| Jack E. Stover | Director | – | – | Dec 22, 2025 |
| Elizabeth Czerepak | Director | – | – | Dec 22, 2025 |
| Life Sciences Intl (Holdings) Inc CK | 10% owner | 12,113,899 | 71.55% | Aug 5, 2026 |
| Defj, Llc | 10% owner | – | – | Aug 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Life Sciences Intl (Holdings) Inc CK 10% owner | Aug 3, 2026 | Conversion | +11,813,859 | – | – | 12,113,899 |
| Life Sciences Intl (Holdings) Inc CK 10% owner | Aug 3, 2026 | Conversion | +2,020,582 | – | – | 14,134,481 |
| Robert Michael Dudley Chief Executive Officer, Director | Sep 28, 2023 | Buy | +98,000 | $0.51 | $49.98K | 180,262 |
| Thomas A. Fitzgerald Chief Financial Officer, Director | Sep 28, 2023 | Buy | +49,350 | $0.51 | $25.17K | 56,318 |
| Robert Michael Dudley Chief Executive Officer, Director | Jun 21, 2023 | Buy | +12,000 | $2.65 | $31.80K | 82,262 |
| Robert Michael Dudley Chief Executive Officer, Director | Jun 20, 2023 | Buy | +6,607 | $2.55 | $16.85K | 70,262 |
| Robert Michael Dudley Chief Executive Officer, Director | Jun 9, 2023 | Buy | +19,000 | $2.76 | $52.44K | 61,155 |
| Robert Michael Dudley Chief Executive Officer, Director | Jun 9, 2023 | Buy | +19,000 | $2.76 | $52.44K | 912,114 |
| Robert Michael Dudley Chief Executive Officer, Director, 10% owner | Sep 14, 2022 | Buy | +20,000 | $1.15 | $23.00K | 893,114 |
| Thomas A. Fitzgerald Chief Financial Officer, Director | Jun 16, 2022 | Buy | +12,000 | $1.27 | $15.24K | 139,377 |
| Robert Michael Dudley Chief Executive Officer, Director, 10% owner | May 31, 2022 | Buy | +2,000 | $1.87 | $3.74K | 873,114 |
| Robert Michael Dudley Chief Executive Officer, Director, 10% owner | May 27, 2022 | Buy | +28,000 | $1.84 | $51.52K | 871,114 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Transcode Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 22,384 shares on Aug 20, 2026 over the last 90 days.
See a number that looks wrong?